Telatinib (BAY 57-9352) [332012-40-5]
Référence A8550-5mg
Conditionnement : 5mg
Marque : APExBIO Technology
Contactez votre distributeur local :
Téléphone : +1 850 650 7790
Telatinib (BAY 57-9352)
Telatinib (BAY 57-9352) is a selective inhibitor of VEGFR2, VEGFR3, c-Kit and PDGFRα with IC50 value of 6 nM, 4 nM, 1 nM and 15 nM, respectively [1].
Vascular endothelial growth factor receptor (VEGFR) is the receptor of VEGF and plays an important role in stimulating vasculogenesis and angiogenesis. Platelet-derived growth factor (PDGF) is a member of growth factors and involves in blood vessel formation. C-Kit is the receptor of a growth factor. Many studies have shown that abnormal of VEGFR, c-Kit and PDGFR are correlated with a variety of tumors [1, 2, 3].
Telatinib is a potent VEGFR2/3, c-Kit and PDGFRα inhibitor. When tested with a panel of tumor cell lines (MDA-MB-231 breast caicinoma, Colo-205 colon carcinoma, DLD-1 colon carcinoma and H460 non-small cell lung carcinoma), Telatinib treatment exhibited inhibition on VEGFR-2 autophosphorylation and PDGF-βwhich involved in the angiogenic process [2].
Telatinib has been used in clinical trails to a variety of cancers treatment and has achieved promising results [2-4].
It is also reported that Telatinib restores tumor cells sensitivity to anticancer drugs and significantly reduced cellular viability by inhibiting ABCG2 expression [3].
References:
[1]. Steeghs, N., et al., Hypertension and rarefaction during treatment with telatinib, a small molecule angiogenesis inhibitor. Clin Cancer Res, 2008. 14(11): p. 3470-6.
[2]. Strumberg, D., et al., Phase I dose escalation study of telatinib (BAY 57-9352) in patients with advanced solid tumours. Br J Cancer, 2008. 99(10): p. 1579-85.
[3]. Sodani, K., et al., Telatinib reverses chemotherapeutic multidrug resistance mediated by ABCG2 efflux transporter in vitro and in vivo. Biochem Pharmacol, 2014. 89(1): p. 52-61.
[4]. Eskens, F.A., et al., Phase I dose escalation study of telatinib, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor 2 and 3, platelet-derived growth factor receptor beta, and c-Kit, in patients with advanced or metastatic solid tumors. J Clin Oncol, 2009. 27(25): p. 4169-76.
| Physical Appearance | A solid |
| Storage | Store at -20°C |
| M.Wt | 409.83 |
| Cas No. | 332012-40-5 |
| Formula | C20H16ClN5O3 |
| Synonyms | BAY 579352;BAY 57 9352 |
| Solubility | insoluble in H2O; insoluble in EtOH; ≥20.5 mg/mL in DMSO |
| Chemical Name | 4-[[4-(4-chloroanilino)furo[2,3-d]pyridazin-7-yl]oxymethyl]-N-methylpyridine-2-carboxamide |
| SDF | Download SDF |
| Canonical SMILES | CNC(=O)C1=NC=CC(=C1)COC2=NN=C(C3=C2OC=C3)NC4=CC=C(C=C4)Cl |
| Shipping Condition | Small Molecules with Blue Ice, Modified Nucleotides with Dry Ice. |
| General tips | We do not recommend long-term storage for the solution, please use it up soon. |
| Description | Telatinib is a potent inhibitor of VEGFR2/3, c-Kit and PDGFRβ with IC50 values of 6 nM/4 nM, 1 nM and 15 nM, respectively. | |||||
| Targets | c-Kit | VEGFR3 | VEGFR2 | PDGFRα | ||
| IC50 | 1 nM | 4 nM | 6 nM | 15 nM | ||